Blockchain Registration Transaction Record

Oncotelic Grants N2B Platform Rights for $12.5M

Oncotelic Therapeutics grants worldwide rights to its nose-to-brain delivery system for biodefense and Alzheimer's in exchange for $12.5M from Lunai Bioworks. Learn about the N2B platform.

This deal matters because it highlights a novel approach to delivering therapeutics directly to the brain, bypassing the blood-brain barrier—a major hurdle in treating neurological diseases and biodefense threats. For investors, it signals Oncotelic's ability to monetize its IP while retaining key assets, potentially accelerating development of treatments for Alzheimer's and other CNS disorders. The partnership with Lunai Bioworks could unlock new medical countermeasures and therapies that directly impact patients suffering from neurodegenerative conditions.